Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hunan Fangsheng Pharmaceutical Co., Ltd. (603998.SS)
CNY10.17
+0.29 (+2.94%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address
No. 299, Jiayun Road 410205
Changsha, CN
Changsha, CN
CEO
Xiaoli Zhou
Website
fangsheng.com.cn
IPO
2014-12-05
ISIN CNE100001VG6
Description
Operating within China, Hunan Fangsheng Pharmaceutical Co., Ltd. is engaged in the complete spectrum of pharmaceutical activities, from research and development to manufacturing and sales. Its diverse product line encompasses tablets, capsules, and granules, addressing a wide array of therapeutic areas such as cardiovascular, cerebrovascular, orthopedic, pediatric, gynecological, traumatology, and anti-infective conditions. The company was established in 2002 and is headquartered in Changsha, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY10.17
+0.29 (+2.94%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7M
Beta
0.29
Float Shares
270.90M
Free Float %
61.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.20% | -3.88% | -9.92% | -20.10% | -13.54% | -11.92% | -5.98% | -30.87% | +43.48% | -21.30% | +80.66% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
10.17
DCF (Unlevered)
35.75
+251.5%
DCF (Levered)
29.58
+190.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.52
Safe zone
Piotroski F-Score
9 / 9
Strong
MOAT Score
5 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-1.8% Q1'26: +10.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+20.7% ★ Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+18.8% ★ Q1'26: +12.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+21.1% ★ Q1'26: +22.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+16.7% ★ Q1'26: +17.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.5% ★ Q1'26: -0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.82× Q1'26: 1.05× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
468.56M
est: 486.00M (-3.6%)
|
534.26M
est: 537.00M (-0.5%)
|
720.77M
est: 613.00M (+17.6%)
|
1.05B
est: 486.00M (+116.3%)
|
1.09B
est: 537.00M (+103.7%)
|
1.28B
est: 613.00M (+108.6%)
|
1.57B
est: 699.00M (+124.2%)
|
1.79B
est: 1.87B (-4.4%)
|
1.63B
est: 1.68B (-2.9%)
|
1.78B
est: 1.82B (-2.4%)
|
1.75B
est: 1.70B (+2.6%)
|
1.93B
1.89B – 1.97B
+13.4% YoY
|
2.17B
2.08B – 2.26B
+12.2% YoY
|
2.40B
2.39B – 2.42B
+11.0% YoY
|
| EBITDA |
139.91M
est: 87.12M (+60.6%)
|
116.42M
est: 96.26M (+20.9%)
|
122.28M
est: 109.88M (+11.3%)
|
141.91M
est: 87.12M (+62.9%)
|
159.48M
est: 96.26M (+65.7%)
|
156.72M
est: 109.88M (+42.6%)
|
177.02M
est: 125.30M (+41.3%)
|
419.20M
est: 335.92M (+24.8%)
|
295.88M
est: 300.61M (-1.6%)
|
381.19M
est: 673.38M (-43.4%)
|
448.63M
est: 629.40M (-28.7%)
|
713.54M
698.03M – 729.06M
+13.4% YoY
|
800.89M
767.24M – 834.54M
+12.2% YoY
|
888.60M
882.38M – 894.83M
+11.0% YoY
|
| EBIT |
120.10M
est: 61.71M (+94.6%)
|
89.08M
est: 68.18M (+30.6%)
|
85.05M
est: 77.83M (+9.3%)
|
97.82M
est: 61.71M (+58.5%)
|
105.70M
est: 68.18M (+55.0%)
|
86.27M
est: 77.83M (+10.8%)
|
109.65M
est: 88.75M (+23.5%)
|
349.53M
est: 237.93M (+46.9%)
|
224.15M
est: 212.92M (+5.3%)
|
308.10M
est: 585.28M (-47.4%)
|
368.05M
est: 547.05M (-32.7%)
|
620.18M
606.70M – 633.67M
+13.4% YoY
|
696.10M
666.85M – 725.34M
+12.2% YoY
|
772.34M
766.93M – 777.74M
+11.0% YoY
|
| Net Income |
90.68M
est: 113.95M (-20.4%)
|
69.76M
est: 120.27M (-42.0%)
|
59.68M
est: 148.14M (-59.7%)
|
72.99M
est: 113.95M (-35.9%)
|
78.91M
est: 120.27M (-34.4%)
|
63.79M
est: 148.14M (-56.9%)
|
70.04M
est: 173.08M (-59.5%)
|
285.85M
est: 290.42M (-1.6%)
|
186.82M
est: 171.61M (+8.9%)
|
255.22M
est: 275.75M (-7.4%)
|
306.39M
est: 306.52M (0.0%)
|
365.29M
355.86M – 376.56M
+19.2% YoY
|
439.15M
423.06M – 455.25M
+20.2% YoY
|
514.36M
511.81M – 541.58M
+17.1% YoY
|
| SGA |
156.48M
est: 206.21M (-24.1%)
|
173.33M
est: 227.85M (-23.9%)
|
305.51M
est: 260.10M (+17.5%)
|
615.88M
est: 206.21M (+198.7%)
|
642.03M
est: 227.85M (+181.8%)
|
624.89M
est: 260.10M (+140.3%)
|
798.49M
est: 296.59M (+169.2%)
|
939.99M
est: 795.14M (+18.2%)
|
804.10M
est: 711.56M (+13.0%)
|
846.29M
est: 843.22M (+0.4%)
|
541.43M
est: 788.15M (-31.3%)
|
893.51M
874.09M – 912.94M
+13.4% YoY
|
1.00B
960.76M – 1.05B
+12.2% YoY
|
1.11B
1.10B – 1.12B
+11.0% YoY
|
| EPS |
0.21
est: 0.26 (-18.9%)
|
0.16
est: 0.27 (-41.5%)
|
0.14
est: 0.34 (-58.4%)
|
0.17
est: 0.26 (-34.4%)
|
0.19
est: 0.27 (-30.5%)
|
0.15
est: 0.34 (-55.4%)
|
0.16
est: 0.39 (-59.3%)
|
0.66
est: 0.66 (+0.0%)
|
0.43
est: 0.39 (+10.3%)
|
0.59
est: 0.63 (-6.3%)
|
0.70
est: 0.71 (-0.7%)
|
0.84
0.81 – 0.86
+18.7% YoY
|
1.00
0.97 – 1.04
+19.9% YoY
|
1.20
1.17 – 1.24
+19.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
279.59M
OE per share TTM
0.64
Owner's Yield
6.43%
Maintenance CapEx ratio
3.87%
Maint CapEx / Avg PPE
57.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.84% | 592.6K | 0.95% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
218.3K
Shares Outstanding
439.08M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chen Bo | Deputy GM & Director | — | male |
| Shi He | Board Secretary | — | male |
| Xiangqi Cao | Financial Director & Accounting Supervisor | — | female |
| Xiaoli Zhou | GM & Chairman | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603998.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
